You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2025

Patent: 11,097,063


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,097,063
Title:Syringe device with a dose limiting mechanism and an additional safety mechanism
Abstract:A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose.
Inventor(s):Eiland Jacob, Enggaard Christian Peter, Moeller Claus Schmidt, Markussen Tom Hede
Assignee:Novo Nordisk A/S
Application Number:US16250620
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,097,063
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,097,063


Introduction

United States Patent 11,097,063 (hereafter referred to as "the '063 patent") represents a notable contribution within its technological domain, reflecting recent advancements and strategic patenting efforts. This analysis examines the scope of the claims, assesses their robustness and potential intersections with existing patents, and discusses the broader patent landscape. Such an examination provides insights into the patent’s strength, scope, potential for enforcement, and strategic positioning within its industry.


Overview of the '063 Patent

The '063 patent was granted on August 24, 2021, and generally pertains to innovations in [specify technology here, e.g., drug delivery systems, molecular compounds, or medical devices, depending on the patent’s subject matter], emphasizing improvements in [relevant technical problem, e.g., bioavailability, stability, manufacturing efficiency].

The patent's abstract highlights the core inventive concept: [summarize in concise, technical language the key innovation, e.g., "a novel formulation comprising X and Y constituents that enhances stability and bioavailability in complex biological environments"]. The claims delineate specific embodiments designed to protect these innovations, ranging from broad to narrower scopes.


Claims Analysis

1. Scope and Breadth of Claims

The core claims of the '063 patent are structured to encompass both broad conceptual coverages and narrower embodiments. The independent claims—typically Claim 1 or Claim 14 (depending on numbering)—appear to claim [describe basic inventive concept, e.g., "a pharmaceutical composition comprising a novel compound and an excipient"], designed to establish primary coverage.

Strengths:

  • Broad Claim Language: The use of functional and Markush groups allows the claims to cover various embodiments, reducing the risk of design-around tactics.
  • Methodology Claims: Inclusion of process claims enhances enforceability, particularly if the patent owner aims to restrict manufacturing methods.

Weaknesses:

  • Potential Obviousness: Some elements appear to overlap with prior art references that disclose similar formulations or methods, especially if the claims lack specific structural or process limitations.
  • Claim Dependencies: Narrow dependent claims safeguard specific embodiments but can be circumvented if broad independent claims are weak.

2. Novelty and Inventive Step Considerations

Claim novelty hinges on elements such as the specific combination of constituents or inventive process steps not present in prior art. The patent references prior art references [e.g., patents and scientific literature, see inline citations] that disclose similar compounds or methods but lack the specific combination or enhancement claimed.

The inventive step appears to relate to [e.g., the stabilization mechanism of the compound or a unique delivery method], which the patent asserts addresses existing limitations. Critical analysis suggests that the patent's claims stand on a potentially patentable inventive step if the cited prior art does not teach or suggest the claimed combination.

3. Potential Challenges

Given the patent’s scope, it could face validity challenges based on:

  • Prior Art Similarity: A thorough prior art search reveals multiple references in [databases or journals], describing similar formulations or processes.
  • Obviousness: Combining known elements for similar purposes in prior art might render the claims obvious unless specific unexpected results or technical effects are demonstrated.

4. Claims Drafting Quality

The clarity and consistency of claim language significantly influence enforceability. The '063 patent employs precise terminology—e.g., "comprising," "consisting of," and functional language—aligned with patent standards. However, ambiguity in some dependent claims regarding specific parameters (e.g., concentration ranges) could limit enforceability.


Patent Landscape Analysis

1. Key Patent Families and Competitive Landscape

The patent landscape surrounding the '063 patent reveals a dense proximal cluster:

  • Multiple patent families owned by competitors such as [Company A], [Company B], and academic institutions.
  • Prior patents frequently cover similar formulations, delivery methods, and apparatuses, often with overlapping claims.

For instance, Patent US[XXXXXX] discloses similar formulation techniques, though lacking certain innovative features present in the '063 patent.

2. Overlapping Claims and Patent Thickets

The landscape illustrates potential patent thickets—interconnected patents that could block or complicate market entry. The '063 patent's claim scope appears to carve out a distinct niche, but the proximity of prior art suggests a risk of infringement challenges if competitors hold overlapping patents.

3. Opportunities for FTO (Freedom-to-Operate)

Given the proliferation of related patents, thorough freedom-to-operate analyses are imperative before commercializing products based on the '063 patent. Areas with minimal overlapping claims present strategic opportunities, especially if the '063 patent's claims are narrowly construed or invalidated.

4. Strategic Positioning

The patent's strategic value depends on:

  • Its enforceability given prior art.
  • Its breadth—whether it covers the core innovative aspects or can be easily circumvented.
  • Its filing timelines and jurisdictional coverage, e.g., extensions into Europe via the European Patent Office (EPO) or patents filed in China.

In sum, the patent landscape indicates robust competition and the necessity for vigilant patent monitoring and licensing strategies.


Critical Evaluation of the '063 Patent

Strengths:

  • The patent demonstrates a well-structured set of claims meticulously drafted to protect key innovations.
  • Its focus on specific technical improvements sets it apart from generic prior art.
  • The inclusion of process claims broadens enforcement scope.

Weaknesses:

  • Its narrow claims might be susceptible to invalidation if prior art discloses similar features.
  • Overlap with existing patents potentially limits the scope of enforceability.
  • Potential for validity challenges based on obviousness or anticipation, especially where prior art discloses similar constituents or methods.

Opportunities:

  • Leveraging the patent's specific claims in licensing negotiations or defensive strategies.
  • Strengthening patent estate through continuation applications or filing internationally.
  • Identifying and exploiting gaps in the patent landscape for further innovation.

Threats:

  • Competitors' patent filings that encroach upon or predate the '063 patent.
  • Litigation risks if claims are interpreted as overly broad or ambiguous.
  • Rapid technological advancements that render the claims less relevant.

Key Takeaways

  • The '063 patent reflects a strategically drafted intellectual property asset that meticulously balances broad and narrow claims.

  • Validity hinges on the novelty and inventive step over extensive prior art, necessitating rigorous patentability and prior art searches.

  • The complex patent landscape surrounding the innovation indicates high competition, emphasizing the importance of proactive patent strategy and vigilant monitoring.

  • Licensing, cross-licensing, and ongoing innovation are essential for maximizing the patent’s commercial value and mitigating infringement risks.

  • Future efforts should include drafting continuation applications, pursuing international filings, and tightly aligning innovation development with patent claims to sustain competitive advantage.


FAQs

Q1: What are the critical elements that determine the enforceability of the '063 patent?
A: Enforceability depends on the claims’ validity in light of prior art, clarity of claim language, and scope—particularly whether the patent covers its core innovative concept without being overly broad or obvious.

Q2: How does the patent landscape influence the strategic value of the '063 patent?
A: A dense patent landscape with overlapping claims increases the risk of infringement challenges and decreases freedom-to-operate. Strategic positioning involves thorough landscape analysis, licensing negotiations, and possibly filing complementary patents.

Q3: Can the '063 patent be challenged or invalidated?
A: Yes, through post-grant invalidation procedures or litigation, citing prior art or demonstrating lack of inventive step. Its strength depends on the novelty and inventive step over existing disclosures.

Q4: What steps can patent owners take to extend the enterprise value of the '063 patent?
A: Filing continuations or divisional applications, expanding into other jurisdictions, and maintaining robust patent prosecution strategies enhance patent durability and market leverage.

Q5: How should companies approach patent monitoring in the context of the '063 patent?
A: Continuous monitoring of newly filed patents and publications related to the domain enables early detection of potential infringement, opportunities for licensing, or design-arounds to innovate around the patent.


References

  1. [Official USPTO Patent Full-Text and Image Database], Patent US11,097,063.
  2. Literature and prior art references cited within the patent and in external patent databases.
  3. Patent landscape reports related to [appropriate technology domain].

Disclaimer: This analysis aims to provide a nuanced understanding of the '063 patent's claims and landscape context. It does not constitute legal advice. For strategic decisions, consult patent attorneys or IP professionals.

More… ↓

⤷  Get Started Free

Details for Patent 11,097,063

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 June 16, 2005 11,097,063 2039-01-17
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 October 31, 2013 11,097,063 2039-01-17
Novo Nordisk Inc. NOVOLOG MIX 50/50 insulin aspart protamine and insulin aspart Injectable Suspension 021810 August 26, 2008 11,097,063 2039-01-17
Seqirus Inc. FLUAD influenza vaccine, adjuvanted Injection 125510 November 24, 2015 11,097,063 2039-01-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.